Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 4/2015

01-04-2015 | Editorial

Reversing Advanced Hepatic Fibrosis in NASH: Clearly Possible, but Widely at Hand?

Authors: Stephen H. Caldwell, Curtis K. Argo

Published in: Digestive Diseases and Sciences | Issue 4/2015

Login to get access

Excerpt

Nonalcoholic fatty liver disease (NAFLD) has become one of the most commonly diagnosed liver conditions, detectable in almost a third of adults in developed countries, with substantially higher prevalence figures if the study population is narrowed to adults with type 2 diabetes mellitus and/or obesity [1]. Depending on the population under study, 10–20 % of NAFLD patients have the potentially progressive form of NAFLD known as NASH or nonalcoholic steatohepatitis. It is the latter group that has been the target of numerous ongoing therapeutic studies in an effort to slow disease progression to cirrhosis, liver failure, and hepatocellular cancer. …
Literature
1.
Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis. 2009;13:511–531.CrossRefPubMed
2.
Clark JM, Brancati FL. Negative trials in nonalcoholic steatohepatitis: why they happen and what they teach us. Hepatology. 2004;39:602–603.CrossRefPubMed
3.
4.
Gawrieh S, Knoedler DM, Saeian K, Wallace JR, Komorowski RA. Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diagn Path. 2011;15:19–24.CrossRef
5.
Guy CD, Suzuki A, Burchette JL, et al. Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease; NASH Clinical Research Network (CRN). Hum Pathol. 2012;43:790–800.CrossRefPubMedCentralPubMed
6.
Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–820.CrossRefPubMedCentralPubMed
7.
Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–1882.CrossRefPubMed
8.
Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-014-3380-3
9.
Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol. 2006;37:1519–1526.CrossRefPubMed
10.
Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011;17:3377–3389.CrossRefPubMedCentralPubMed
11.
Dixon JB. Surgical management of obesity in patients with morbid obesity and nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:129–146.CrossRefPubMed
12.
Caiazzo R, Lassailly G, Leteurtre E. Gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg. 2014;260:893–899.CrossRefPubMed
13.
Oh S, Shida T, Yamagishi K, et al. Moderate to vigorous physical activity volume is an important factor for managing non-alcoholic fatty liver disease: a retrospective study. Hepatology. (Epub ahead of print). doi:10.​1002/​hep.​27544.
14.
Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. (Epub ahead of print). doi:10.​1016/​j.​jhep.​2014.​08.​036.
15.
16.
Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35:66–75.CrossRefPubMedCentralPubMed
17.
Argo CK, Iezzoni JC, Al-Osaimi AM, Caldwell SH. Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? J Clin Gastroenterol. 2009;43:565–568.CrossRefPubMed
18.
Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. Epub. 12/7/2014.
19.
Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971.CrossRefPubMedCentralPubMed
20.
Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56:944–951.CrossRefPubMed
21.
Kozlitina J, Smagris E, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. (Epub ahead of print). doi:10.​1038/​ng.​2901.
22.
van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500–1508.CrossRefPubMed
23.
Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.CrossRefPubMedCentralPubMed
24.
Lee YM, Low HC, Lim LG, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc. 2012;76:756–760.CrossRefPubMed
Metadata
Title
Reversing Advanced Hepatic Fibrosis in NASH: Clearly Possible, but Widely at Hand?
Authors
Stephen H. Caldwell
Curtis K. Argo
Publication date
01-04-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3540-0

Other articles of this Issue 4/2015

Digestive Diseases and Sciences 4/2015 Go to the issue

Original Article

Helicobacter pylori Infection Activates the Akt–Mdm2–p53 Signaling Pathway in Gastric Epithelial Cells

Original Article

High-Fat Diet Promotes Neuronal Loss in the Myenteric Plexus of the Large Intestine in Mice

Original Article

Association of Serotonin Transporter Promoter Polymorphism (5-HTTLPR) with Microscopic Colitis and Ulcerative Colitis

REVIEWER ACKNOWLEDGMENT

Acknowledgment of 2014 Reviewers

Original Article

Foods Provoking and Alleviating Symptoms in Gastroparesis: Patient Experiences

Original Article

Comparative Effectiveness of Pyruvate Kinase M2 in Bile, Serum Carbohydrate Antigen 19-9, and Biliary Brushings in Diagnosing Malignant Biliary Strictures
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits